HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stanislas Pol Selected Research

daclatasvir

10/2020Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort.
1/2018Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.
1/2018Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
1/2017Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis.
5/2016Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
2/2016Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
1/2016Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life.
6/2015Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.
5/2015Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
2/2015Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stanislas Pol Research Topics

Disease

117Infections
02/2021 - 07/2002
97Fibrosis (Cirrhosis)
06/2022 - 07/2002
55Chronic Hepatitis C
06/2022 - 01/2002
29Liver Diseases (Liver Disease)
10/2022 - 01/2002
28Hepatitis C
06/2022 - 07/2002
27Hepatocellular Carcinoma (Hepatoma)
06/2022 - 09/2008
26Liver Cirrhosis (Hepatic Cirrhosis)
06/2022 - 03/2003
26Chronic Hepatitis B
02/2022 - 02/2001
16Hepatitis B
01/2019 - 03/2003
15Hepatitis
10/2021 - 03/2004
11Chronic Hepatitis (Chronic Active Hepatitis)
10/2021 - 07/2002
11Coinfection
12/2019 - 09/2007
10Persistent Infection
01/2021 - 10/2005
9HIV Infections (HIV Infection)
11/2021 - 03/2004
9Vasculitis (Vasculitides)
01/2019 - 10/2006
8Neoplasms (Cancer)
11/2021 - 03/2004
8Chronic Renal Insufficiency
10/2018 - 06/2015
7Virus Diseases (Viral Diseases)
01/2021 - 10/2004
7Cryoglobulinemia
01/2019 - 07/2002
6Lymphoma (Lymphomas)
01/2018 - 03/2015
5Disease Progression
01/2022 - 05/2007
5Portal Hypertension
01/2022 - 01/2007
5Liver Neoplasms (Liver Cancer)
10/2021 - 01/2017
5Viremia
10/2020 - 07/2010
4Hypertension (High Blood Pressure)
02/2022 - 01/2018
4Non-alcoholic Fatty Liver Disease
02/2021 - 03/2004
4Inflammation (Inflammations)
01/2021 - 02/2005
4Anemia
03/2014 - 04/2009
3Hemorrhage
01/2022 - 09/2008
3Ascites
01/2022 - 01/2007
3Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021 - 03/2004
3End Stage Liver Disease
04/2019 - 08/2003
3Body Weight (Weight, Body)
03/2014 - 04/2009
3Exanthema (Rash)
01/2013 - 04/2009
2Esophageal and Gastric Varices (Esophageal Varices)
06/2022 - 01/2019
2Dyslipidemias (Dyslipidemia)
02/2022 - 01/2021
2COVID-19
10/2021 - 02/2021
2Alcoholism (Alcohol Abuse)
10/2021 - 05/2013
2Acquired Immunodeficiency Syndrome (AIDS)
10/2021 - 01/2011

Drug/Important Bio-Agent (IBA)

79Antiviral Agents (Antivirals)IBA
06/2022 - 01/2006
69Ribavirin (Virazole)FDA LinkGeneric
10/2020 - 07/2002
47InterferonsIBA
06/2019 - 11/2004
19RNA (Ribonucleic Acid)IBA
06/2019 - 07/2002
18Protease Inhibitors (Protease Inhibitor)IBA
04/2019 - 01/2006
14SofosbuvirIBA
01/2021 - 02/2014
13daclatasvirIBA
10/2020 - 09/2012
12Proteins (Proteins, Gene)FDA Link
08/2021 - 02/2001
10telaprevirIBA
01/2015 - 04/2009
9Pharmaceutical PreparationsIBA
01/2022 - 08/2007
9Tenofovir (Viread)FDA Link
01/2021 - 01/2007
9VaccinesIBA
01/2021 - 01/2003
8Biomarkers (Surrogate Marker)IBA
01/2022 - 09/2006
8DNA (Deoxyribonucleic Acid)IBA
01/2021 - 10/2006
8Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2019 - 02/2006
7grazoprevirIBA
01/2020 - 03/2015
7elbasvirIBA
01/2020 - 03/2015
7NucleosidesIBA
06/2015 - 03/2008
7Interferon-alpha (Interferon Alfa)IBA
05/2015 - 07/2002
7peginterferon alfa-2a (Pegasys)FDA Link
02/2015 - 01/2008
7N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
01/2015 - 12/2011
6entecavirFDA Link
01/2021 - 08/2011
6Hepatitis B e AntigensIBA
03/2018 - 05/2006
5BilirubinIBA
06/2022 - 12/2005
5Biological ProductsIBA
04/2019 - 09/2004
5faldaprevirIBA
01/2016 - 06/2011
5asunaprevirIBA
05/2015 - 01/2013
5Lamivudine (Epivir)FDA Link
10/2011 - 10/2005
4CoffeeFDA Link
06/2022 - 01/2019
4alpha-Fetoproteins (alpha-Fetoprotein)IBA
08/2021 - 06/2008
4glecaprevir and pibrentasvirIBA
01/2021 - 10/2017
4Immunoglobulins (Immunoglobulin)IBA
03/2018 - 05/2008
4NucleotidesIBA
05/2016 - 06/2009
4AntigensIBA
11/2015 - 03/2005
4Sorafenib (BAY 43-9006)FDA Link
12/2012 - 02/2011
4AntibodiesIBA
04/2011 - 10/2004
3AlbuminsIBA
06/2022 - 12/2012
3Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2022 - 08/2012
3gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA
01/2022 - 02/2009
3EnzymesIBA
02/2021 - 03/2004
3Hepatitis B Vaccines (Hepatitis B Vaccine)IBA
03/2018 - 04/2009
3pibrentasvirIBA
01/2018 - 10/2017
3glecaprevirIBA
01/2018 - 10/2017
3sofosbuvir drug combination ledipasvirIBA
01/2017 - 04/2015
3CreatinineIBA
01/2017 - 12/2012
3ledipasvirIBA
01/2017 - 07/2014
3deleobuvirIBA
01/2016 - 12/2011
3Alanine Transaminase (SGPT)IBA
01/2016 - 11/2010
3ErythropoietinFDA Link
03/2014 - 08/2011
3Didanosine (Videx)FDA LinkGeneric
03/2008 - 12/2004

Therapy/Procedure

83Therapeutics
01/2022 - 08/2003
13Liver Transplantation
01/2022 - 01/2007
11Kidney Transplantation
01/2019 - 01/2002
10Transplantation
01/2018 - 07/2002
8Highly Active Antiretroviral Therapy (HAART)
05/2012 - 08/2003
6Renal Dialysis (Hemodialysis)
01/2018 - 07/2002
5Duration of Therapy
03/2019 - 02/2012
4Aftercare (After-Treatment)
06/2022 - 01/2018
4Blood Transfusion (Blood Transfusions)
01/2020 - 11/2012
3Drug Therapy (Chemotherapy)
01/2018 - 05/2008
3Contraindications
09/2013 - 08/2011